OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy

  OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial
Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell
                                 Lung Cancer

OGX-427 ORCA™ Program Expands to Include Second Phase 2 Trial in Patients with
Advanced Lung Cancer

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, May 23, 2013

BOTHELL, Wash.and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for
the initiation of the Cedar™ clinical trial, an investigator-sponsored,
randomized, open-label Phase 2 trial evaluating OGX-427 in previously
untreated patients with advanced squamous cell lung cancer.

This trial will be the seventh randomized Phase 2 clinical trial evaluating
OGX-427 in the treatment of advanced cancers and will investigate whether
adding OGX-427 to gemcitabine and carboplatin therapy can extend
progression-free survival (PFS) outcomes.

Cedar will randomize approximately 140 patients to receive either OGX-427 plus
gemcitabine and carboplatin therapy, or gemcitabine and carboplatin therapy
alone. The primary objective will be PFS, with secondary objectives to
evaluate tumor response rates, overall survival, safety, tolerability, and
health-related quality of life. Additional analyses will be conducted to
determine the effect of therapy on heat shock protein 27 (Hsp27) levels and to
explore potential biomarkers that may help predict response to treatment.

"Despite recent advances for the treatment of lung cancer, limited progress
has been made to improve survival outcomes for patients with squamous cell
carcinoma," stated Prof. Peter Schmid MD PhD FRCP, Director of the
Barts/Brighton Experimental Cancer Medicine Centre and the primary
investigator on the trial. "Given the preclinical evidence demonstrating
significant overexpression of Hsp27 in squamous cell lung cancers, the ability
of OGX-427 to inhibit the production of this protein that is linked with
resistance to chemotherapy, and the viable combination with gemcitabine and
carboplatin, we are hopeful that Cedar will provide meaningful data on the
potential of OGX-427 to improve survival outcomes in this difficult-to-treat

The trial is being conducted by the UK National Cancer Research Network and
the UK Experimental Cancer Medicine Network and will involve 35 centres in the

Cedar will be the second randomized Phase 2 trial of OGX-427 in advanced lung
cancer. OncoGenex also recently announced plans to initiate the Spruce™
trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial
evaluating OGX-427 in combination with carboplatin and pemetrexed in patients
with previously untreated, advanced, non-squamous, non-small cell lung cancer
(NSCLC). Spruce is being conducted in partnership with the Sarah Cannon
Research Institute (SCRI) and is expected to begin enrollment later this year.

Lung cancer is the most common cancer worldwide, with approximately 1.6
million new cases per year. It is the leading cause of cancer death among both
men and women in the United States, with approximately 160,000 people expected
to die from the disease in 2013. About 80 percent of all lung cancers are
identified as non-small cell lung cancer (NSCLC), and a majority of these are
metastatic, or advanced, at diagnosis. Non-squamous histology NSCLC includes
adenocarcinoma and large cell carcinoma, and accounts for more than half of
all diagnoses. Squamous histology NSCLC accounts for about 25 to 30 percent of
all lung cancer cases. Although specific targeted therapy has been identified
for a minority of patients, chemotherapy remains the backbone of treatment for
the majority of patients with lung cancer.

OGX-427 is a once-weekly intravenous (IV) drug that is designed to inhibit
production of heat shock protein (Hsp27) to disable cancer cells' defenses and
overcome treatment resistance. Hsp27 is an intracellular protein that protects
cancer cells by helping them survive, leading to resistance and more
aggressive cancer phenotypes.

The ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program
encompasses clinical trials of OGX-427. Phase 2 clinical trials are underway
in bladder, lung, pancreatic and prostate cancers. For more information on
OGX-427 and ORCA, please visit www.OncoGenex.com.

OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd. have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen
is currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with advanced,
unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical
development and OGX-225 is currently in pre-clinical development. More
information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning our anticipated
product development activities, such as expected clinical trial completion and
design and statements regarding the potential benefits and potential
development of our product candidates. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current expectations
and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those
described in the forward-looking statements, including, among others, the risk
that our product candidates will not demonstrate the hypothesized or expected
benefits, the risk of delays in our expected clinical trials, the risk that
new developments in the rapidly evolving cancer therapy landscape require
changes in our clinical trial plans or limit the potential benefits of our
product candidates and the other factors described in our risk factors set
forth in our filings with theSecurities and Exchange Commissionfrom time to
time, including the Company's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be required
by applicable law.

ORCA™, Cedar™ and Spruce™ are registered trademarks of OncoGenex
Pharmaceuticals, Inc.

SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://www.OncoGenex.com
Contact: Media: Jaime Welch, jwelch@oncogenex.com, 604-630-5403; or Investor
Relations: Susan Specht, sspecht@oncogenex.com , 425-686-1535
Press spacebar to pause and continue. Press esc to stop.